Xenon Pharmaceuticals (XENE) Misses Q1 EPS by 2c

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q1 EPS of ($0.23), $0.02 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $601 thousand versus the consensus estimate of $3.3 million.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

You May Also Be Interested In

• Oppenheimer turns cautious on major U.S. banks, favors alternative asset managers
• AeroVironment (AVAV) PT Lowered to $280 at Canaccord
• Logitech dips as BofA downgrades stock on demand outlook concerns